192 related articles for article (PubMed ID: 36196439)
1. Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.
Shortridge D; Deshpande LM; Streit JM; Castanheira M
JAC Antimicrob Resist; 2022 Oct; 4(5):dlac097. PubMed ID: 36196439
[TBL] [Abstract][Full Text] [Related]
2. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
3. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
[TBL] [Abstract][Full Text] [Related]
4. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
Shortridge D; Carvalhaes C; Deshpande L; Castanheira M
J Antimicrob Chemother; 2021 Sep; 76(10):2600-2605. PubMed ID: 34302173
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
6. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
[TBL] [Abstract][Full Text] [Related]
7. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
Bhowmick T; Weinstein MP
Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
[TBL] [Abstract][Full Text] [Related]
8. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
[TBL] [Abstract][Full Text] [Related]
10. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of carbapenemase genes among carbapenem-nonsusceptible
Castanheira M; Deshpande LM; Mendes RE; Doyle TB; Sader HS
JAC Antimicrob Resist; 2022 Oct; 4(5):dlac098. PubMed ID: 36196444
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
Castanheira M; Huband MD; Mendes RE; Flamm RK
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
[TBL] [Abstract][Full Text] [Related]
14. Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant
Shrief R; El-Ashry AH; Mahmoud R; El-Mahdy R
Infect Drug Resist; 2022; 15():6203-6214. PubMed ID: 36324668
[TBL] [Abstract][Full Text] [Related]
15. Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible
Zhang J; Jia P; Zhu Y; Zhang G; Xu Y; Yang Q
Front Med (Lausanne); 2021; 8():643194. PubMed ID: 33937287
[No Abstract] [Full Text] [Related]
16. CARB-ES-19 Multicenter Study of Carbapenemase-Producing
Cañada-García JE; Moure Z; Sola-Campoy PJ; Delgado-Valverde M; Cano ME; Gijón D; González M; Gracia-Ahufinger I; Larrosa N; Mulet X; Pitart C; Rivera A; Bou G; Calvo J; Cantón R; González-López JJ; Martínez-Martínez L; Navarro F; Oliver A; Palacios-Baena ZR; Pascual Á; Ruiz-Carrascoso G; Vila J; Aracil B; Pérez-Vázquez M; Oteo-Iglesias J;
Front Microbiol; 2022; 13():918362. PubMed ID: 35847090
[TBL] [Abstract][Full Text] [Related]
17.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
18. Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates.
Castanheira M; Doyle TB; Collingsworth TD; Sader HS; Mendes RE
J Antimicrob Chemother; 2021 Nov; 76(12):3125-3134. PubMed ID: 34459890
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible
Kazmierczak KM; Karlowsky JA; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0200020. PubMed ID: 33972241
[TBL] [Abstract][Full Text] [Related]
20. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
Sader HS; Mendes RE; Carvalhaes CG; Kimbrough JH; Castanheira M
Open Forum Infect Dis; 2023 Feb; 10(2):ofad046. PubMed ID: 36846612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
